Hatch Waxman Litigation
O’Melveny is home to some of the nation’s preeminent practitioners in Hatch-Waxman and biologics litigation. Offering the technical depth of an intellectual property boutique, coupled with the resources of an elite global litigation powerhouse, our team provides unparalleled service to innovator companies.
As scientists, and litigators, we know the pharmaceutical industry. We know chemistry. We know biotechnology. We know formulation technology. We know the law. And we know the regulatory environment. Our team has handled dozens of significant cases for drug manufacturers whose patents were threatened by generic challengers, and protected billions in sales revenue.
Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.
In the News
February 10, 2023Law360: Beltway Moves: IP Moves at O’Melveny, Duane Morris
February 1, 2023O’Melveny Welcomes Leading Intellectual Property Litigator Robert F. Shaffer to its Washington, DC Office
“A big noise in the fiercely competitive patent infringement arena.”
- IAM 1000